Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has launched Medidata Rave Lite, an extension of its flagship clinical research software, Medidata Rave EDC. Designed specifically for Phase I and IV clinical trials, Rave Lite brings advanced electronic clinical data capture (EDC), management, and analytics capabilities to market segments that have traditionally lacked access to cutting-edge technology. The new solution offers a flexible pricing model, making it accessible to organizations of all sizes, therapeutic areas, and stages of development.
While EDC is a critical component of clinical trials, technology fragmentation across different trial phases can create integration issues and delay launches. This challenge is especially pronounced in early and late-stage studies. Medidata, with experience in over 34,000 trials, aims to overcome these hurdles with Rave Lite, providing an exceptional option for Phase I and IV studies.
The integration of Medidata Designer allows study teams to quickly and accurately design trials, while ongoing AI enhancements help minimize potential study configuration errors and maintain data integrity. Rave Lite ensures a seamless user experience without compromising the robust capabilities of Rave EDC.
“Rave Lite addresses a significant need in the market for early and late-stage trials, offering a streamlined solution built on our reliable Rave EDC platform,” said Tom Doyle, Chief Technology Officer of Medidata. “It allows customers to use the same EDC system across all phases, providing the flexibility to scale studies while upholding the high standards associated with Medidata solutions.”
Recently recognized as a leading vendor in Everest Group’s inaugural PEAK Matrix® for its ability to optimize clinical trials for sponsors and contract research organizations (CROs), Rave EDC continues to set the benchmark for data quality and integrity.
Medidata will showcase Rave Lite at NEXT New York, the company’s flagship clinical trial conference, on November 13-14 in New York City. The solution will be available to customers starting early 2025.
About Medidata
Medidata is supporting clinical trials with innovative digital solutions to enable smarter treatments and improve human health. In its 25 years, Medidata has supported more than 34,000 trials covering more than 10 million patients. With disruptive technology innovation, Medidata provides industry-leading expertise, analytics-based insights and the world’s largest patient-level historical clinical trial data set. More than 1 million registered users from approximately 2,200 customers around the world trust Medidata’s seamlessly integrated end-to-end platform to improve patient experience, accelerate clinical breakthroughs, and help bring innovative treatments to market faster. Medidata is a brand of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), headquartered in New York City, and has been named a leader by Everest Group and IDC. For more information, please visit www.medidata.com and follow us at @Medidata.
About Dassault Systèmes
Dassault Systèmes is committed to advancing human progress. We provide companies and customers with a collaborative virtual environment to imagine sustainable innovations. Using our 3DEXPERIENCE platform and applications, our customers have a profound impact on building a more sustainable world by creating a virtual twin of the real world to redefine how they create, produce and manage their products throughout their lifecycle. The advantage of the experience economy is that it puts people at the center, benefiting everyone, including consumers, patients and residents. Dassault Systèmes brings value to more than 350,000 customers of all sizes and in all industries in more than 150 countries
